Efficacy and safety of the ALK inhibitor alectinib in ALK plus non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett Gordon Maxwell, Lena, Herve, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander I., Zeaiter, Ali Hassan, Bordogna, Walter, Balas, Bogdana, Golding, Sophie, Morcos, Peter N., Kim, Dong-Wan

authors

Publication Date

  • May 20, 2015

webpage

published in

category

volume

  • 33

issue

  • 15

WoS Citations

  • 13

WoS References

  • 0